RTW INVESTMENTS, LP - 12 Dec 2024 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Reporting relationship: Director, Other*, 10%+ Owner
Issuer ticker: RCKT
Reported as of: 12 Dec 2024
Net transaction value: +$4,996,000
SEC form: 4
Accepted by SEC: 16 Dec 2024, 19:38:22 UTC
Prior SEC filing: 16 Jan 2024
Next SEC filing: 24 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Roderick Wong, for RTW Investments, LP, By: Roderick Wong, M.D., its Managing Partner

Key filing fact

RTW INVESTMENTS, LP filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 16 Dec 2024.

Key facts

This page summarizes RTW INVESTMENTS, LP's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Dec 2024, 19:38.

Change

Previous filing in this sequence was filed on 16 Jan 2024.
Current net transaction value: +$4,996,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RCKT transaction Derivative

Pre-funded Warrant (right to buy)

Award

Transaction value: $4,996,000
Shares: +400,000
Change %: +13%
Price: $12.49
Shares after: 3,526,955
Date: 12 Dec 2024
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 400,000
Exercise price: $0.0100
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Pre-Funded Warrant was purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended.

Footnote F2

Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may, at any time and from time to time on or after December 12, 2024, exercise the Pre-Funded Warrant until exercised in full. The Pre-Funded Warrant reported herein contains an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrant until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the "Blocker"). Due to the Blocker, the Pre-Funded Warrant beneficially owned by the Reporting Persons is not presently exercisable.

Footnote F3

This Form 4 is being filed by each of (i) RTW Investments, LP (the "Adviser") with respect to the securities held by certain investment funds managed by the Adviser (the "RTW Funds") and (ii) Roderick Wong, M.D. ("Dr. Wong"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors.

SEC remarks

The Adviser may be deemed to be a director by deputization for purposes of Section 16 under the Securities Exchange Act of 1934 by virtue of the fact that each of Dr. Wong, Naveen Yalamanchi, M.D., who serves as a Partner and Portfolio Manager of the Adviser, and Gotham Makker, who serves as a Partner and Head of Strategic Investments of the Adviser, currently serves on the board of directors of the Issuer. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.